Pfizer: Bearish Setup Points to Further Downside Risk Pfizer, Inc.BATS:PFECrowdWisdomTradingCurrent Price: $23.76 Direction: SHORT Targets: - T1 = $22.50 - T2 = $21.50 Stop Levels: - S1 = $24.50 - S2 = $25.30 **Wisdom of Professional Traders:** This analysis synthesizes insights from thousands of professional traders and market experts who have been following Pfizer’s recent struggles. Combining the collective intelligence of skilled professionals helps pinpoint high-probability trade setups that align with developing market sentiment. Currently, the consensus among traders suggests that Pfizer could continue facing downside pressure due to deteriorating fundamentals and bearish technical indicators. **Key Insights:** Pfizer has encountered significant revenue headwinds in 2025, primarily stemming from the expiration of patents on key drugs and muted vaccine demand. Reduced fulfillment for COVID-related products has weighed heavily on the company's earnings potential, leading to revised guidance for the fiscal year. Additionally, increasing competition in the immunology and oncology spaces further pressures Pfizer's growth story as it strives to pivot toward pipeline development and innovation for long-term recovery. From a technical perspective, Pfizer's stock remains bearish after failing to hold a support level above $25 earlier this month. The stock’s Relative Strength Index (RSI) lands below 40, suggesting persistent oversold conditions, while volume data confirms the dominance of sellers. With its 50- and 200-day moving averages trending downward, a continued bearish trend appears probable ahead of Pfizer’s next earnings release in Q4. Traders report resistance near $25.50, a level the stock is struggling to reclaim, setting the stage for further declines. **Recent Performance:** Pfizer’s stock has dropped substantially over the last quarter, declining roughly 16% from its 2025 peak of $28. The healthcare sector as a whole has been underperforming, with Pfizer particularly impacted due to broader market rotations favoring cyclical stocks amidst elevated interest rates. The stock’s downward trajectory reflects clear institutional selling, particularly in high-volume days driving prices lower. This sustained weakness positions the stock deep below critical moving average levels—a bearish signal for technical traders. **Expert Analysis:** Market analysts have downgraded expectations for Pfizer’s year-end financial results. Rising R&D expenses alongside declining margins are seen as major obstacles for the company, even as it doubles down on its strategic initiatives like mRNA vaccine development and oncology advancements. Technical professionals highlight that the break below $25 signals bearish momentum, with lower highs and consistent failures to reverse selling pressure confirming short-term downside risk. Traders also note a bearish MACD crossover, reinforcing negative sentiment and suggesting further weakness. **News Impact:** Pfizer’s recent restructuring plans and ongoing cost-cutting measures have dominated headlines but failed to instill confidence among investors. The company faces growing skepticism regarding its ability to sustain long-term growth in core areas like immunology. Additionally, disappointing data on COVID-19 vaccine-related revenue has underscored challenges in adapting to waning pandemic-related demand. These developments are fostering bearish sentiment and keeping downward pressure on the stock. **Trading Recommendation:** Pfizer’s sustained weakness presents a compelling short opportunity for traders looking to capture downside potential. The break below key support levels, coupled with bearish technical signals and disappointing fundamentals, suggests the stock could revisit targets in the $22-$21 range. Initiating a short position at current levels could deliver a favorable risk-reward setup, particularly with stop-loss levels firmly placed above $24.50 and $25.30 to mitigate potential reversals. Short sellers can leverage this momentum to capitalize on further downside risks. Do you want to save hours every week? Register for the free weekly update in your language!